Lexicon Pharmaceuticals, Inc. - LXRX
About Gravity Analytica
Recent News
- 12.10.2025 - Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
- 12.05.2025 - Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
- 11.25.2025 - Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
- 11.11.2025 - Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
- 11.08.2025 - Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
- 11.06.2025 - Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
- 11.04.2025 - Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
- 10.30.2025 - Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
- 10.14.2025 - Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
- 10.08.2025 - Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain